Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

I'm a board-certified endocrinologist and , contrary to popular belief, choosing GLP-1 treatment isn't the ' easy way out.' ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Food-packed tables and endless spirits can present a special challenge for those taking GLP-1 medications like Wegovy, ...

Doctors explain the 4 common mistakes that lead to rebound weight gain after stopping Ozempic, and how to stay on track.

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...